Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy

Journal of Endocrinological Investigation

Volumn 22, Issue 9, 1999, Pages 708-735

  Pugliese, Giuseppe ^b,c   Pricci, F ^a   Romeo, G ^b   Leto, G ^b   Amadio, L ^b   Iacobini, C ^b   Di Mario, U ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Diabet Endocrinol Metab Found   (Italy)

Author keywords

Adhesion molecules; Advanced glycation endproducts; Apoptosis; Cell proliferation; Cytokines; Diabetic nephropathy; Extracellular matrix; Hexosamine pathway; Insulin like growth factor I; Oxidative stress; Polyol pathway; Protein kinase C; Transforming growth factor

Indexed keywords

CYTOKINE; PROTEIN KINASE C;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLOMERULUS; GLYCATION; HYPERGLYCEMIA; KIDNEY DISEASE; OXIDATIVE STRESS; REVIEW;

EID: 0032757157     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343635     Document Type: Review

References (300)

1. Steffes M.W., Osterby R., Chavers B., Mauer S.M. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989, 38: 1077-1081.
2. Mogensen C.E., Anderson M.J.F. Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: normalization by insulin-treatment. Diabetologia 1975, 11: 221-224.
3. Cortes P., Dumler F., Goldman J., Levin N.W. Relationship between renal function and metabolic alterations in early streptozotocin-induced diabetes in rats. Diabetes 1987, 36: 80-87.
4. Seyer-Hansen K. Renal hypertrophy in experimental diabetes mellitus. Kidney Int. 1983, 23: 643-646.
5. Krolewski A.S., Warram J.H., Christlieb A.R., Busick EJ., Kahn C.R. The changing natural history of nephropathy in Type I diabetes Am. J. Med. 1985, 78: 785-794.
6. Striker G.E., Peten E.P., Carome M.A., Pesce C.M., Schmidt K., Yang C.-W., Elliot S.J., Striker L.J. The kidney disease of diabetes mellitus (KDDM): a cell and molecular biology approach. Diabetes Metab. Rev. 1993, 9: 37-56.
7. Rabkin R., Fervenza F.C. Renal hypertrophy and kidney disease in diabetes. Diabetes Metab. Rev. 1996, 12: 217-241.
8. Klahr S., Schreiner G., Ichikawa I. The progression of renal disease. N. Engl. J. Med. 1988, 318: 1657-1666.
9. Pugliese G., Tilton R.G., Williamson J.R. Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab. Rev. 1991, 7: 35-59.
10. Doria A., Warram J.H., Krolewski A.S. Genetic susceptibility to nephropathy in insulin-dependent diabetes: from epidemiology to molecular genetics. Diabetes Metab. Rev. 1995, 11: 287-314.
11. Ziyadeh F.N. The extracellular matrix in diabetic nephropathy. Am. J. Kidney Dis. 1993, 22: 736-744.
12. Furness P.N. Extracellular matrix and the kidney. J. Clin. Pathol. 1996, 49: 355-359.
13. Karttunen T., Risteli J., Autio-Harmainen H., Risteli L. Effect of age and diabetes on type IV collagen and laminin in human kidney cortex. Kidney Int. 1986, 30: 386-391.
14. Nerlich A., Schleicher E. Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am. J. Pathol. 1991, 139: 889-899.
15. Mohan P.S., Carter W.G., Spiro R.G. Occurrence of type VI collagen in extracellular matrix of renal glomeruli and its increase in diabetes. Diabetes 1990, 39: 31-37.
16. Esposito C., Striker L.J., Patel A., Peten E., Liu Z.H., Sakai H., Striker G.E., for the International Study Group for Molecular Study of Kidney Biopsies. Molecular analysis of glomerular diseases in renal biopsies: initial results of a collaborative studies. Proc. Assoc. Am. Physicians 1996, 108: 209-217.
17. Falk R.J., Scheinman J.I., Mauer S.M., Michael A.F. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes 1983, 32 (Suppl. 2): 34-39.
18. Abrass C.K., Peterson C.V., Raugi G.J. Phenotypic expression of collagen types in mesangial matrix of diabetic and nondiabetic rats. Diabetes 1988, 37: 1695-1702.
19. Glick A.D., Jacobson H.R., Haralson M.A. Mesangial deposition of type I collagen in human glomerulosclerosis. Hum. Pathol. 1992, 232: 1373-1379.
20. Shimomura H., Spiro R.G. Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes: decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 1987, 36: 374-381.
21. Truong L.D., Pindur J., Barrios R., D'Agati V., Lechago J., Suki W., Majesky M. Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. Kidney Int. 1994, 45: 201-210.
22. Wu V.Y., Wilson B., Cohen M.P. Disturbances in glomerular basement membrane glycosaminoglycans in experimental diabetes. Diabetes 1987, 36: 679-683.
23. Parthasarathy N., Spiro R.G. Effect of diabetes on the glycosaminoglycan component of the human glomerular basement membrane. Diabetes 1982, 31: 738-741.
24. Kanwar Y.S., Rosenweig L.J., Linker A., Jakubowski M.L. Decreased de novo synthesis of glomerular proteoglycans in diabetes: biochemical and autoradiographic evidence. Proc. Natl. Acad. Sci. USA 1983, 80: 2272-2275.
25. Templeton D.M. Retention of glomerular basement membrane-proteoglycans accompanying loss of anionic site staining in experimental diabetes. Lab. Invest. 1989, 61: 202-211.
26. 4 proteoglycan by heparin in streptozotocin-induced diabetic rats. Diabetes 1989, 38: 130-139.
27. McCarthy K.J., Abrahamson D.R., Bynum K.R., St. John P.L., Couchman J.R. Basement membrane-specific chondroitin sulfate proteoglycan is abnormally associated with the glomerular capillary basement membrane of diabetic rats. J. Histochem. Cytochem. 1994, 42: 473-484.
28. Ayo S.H., Radnik R.A., Garoni J.A., Glass W.F. II, Kreisberg J.I. High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am. J. Pathol. 1990, 136: 1339-1348.
29. Ayo S.H., Radnik R.A., Glass W.F. II, Garoni J.A., Rampt E.R., Appling D.R., Kreisberg J.I. Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am. J. Physiol. 1991, 260: F185-F191.
30. Pugliese G., Pricci F., Pugliese F., Menè P., Lenti L., Andreani D., Galli G., Casini A., Bianchi S., Rotella C.M., Di Mario U. Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells. Diabetes 1994, 43: 478-490.
31. Pugliese G., Pricci F., Locuratolo N., Romeo G., Romano G., Giannini S., Cresci B., Galli G., Rotella C.M., Di Mario U. Increased activity of the insulin-like growth factor system in mesangial cells cultured in high glucose conditions: relation to glucose-enhanced extracellular matrix production. Diabetologia 1996, 39: 775-784.
32. Fukui M., Nakamura T., Ebihara I., Shirato I., Tomino Y., Koide H. ECM gene expression and its modulation by insulin in diabetic rats. Diabetes 1992, 41: 1520-1527.
33. Pugliese G., Pricci F., Pesce C.M., Romeo G., Lenti E., Vetri M., Caltabiano V., Purrello F., Di Mario U. Early, but not advanced, experimental diabetic glomerulopathy is reversed by pancreatic islet transplants. Correlation with glomerular extracellular matrix mRNA levels. Diabetes 1997, 46: 1198-1206.
34. Roy S., Sala R., Cagliero E., Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc. Natl. Acad. Sci. USA 1990, 87: 404-408.
35. Phan-Thanh L., Robert L., Derouette J.C., Labat-Robert J. Increased biosynthesis and processing of fibronectinin fibroblasts from diabetic mice. Proc. Natl. Acad. Sci. USA 1987, 84: 1911-1915.
36. Zheng F., Striker G.E., Esposito C., Lupia E., Striker L.J. Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Kidney Int. 1998, 54: 1999-2007.
37. Pugliese G., Pricci F., Menè P., Romeo G., Nofroni I., Giannini S., Cresci B., Galli G., Rotella C.M., Di Mario U., Pugliese F. High glucose unmasks a genetic predisposition to enhanced extracellular matrix production in mesangial cells from rats with spontaneous glomerulosclerosis. J. Am. Soc. Nephrol. 1997, 8: 406-414.
38. Reckelhoff J.F., Tygart V.L., Mitias M.M., Walcott J.L. STZ-induced diabetes results in decreased activity of glomerular cathepsin and metalloproteinase in rats. Diabetes 1993, 42: 1425-1432.
39. Nakamura T., Fukui M., Ebihara I., Osada S., Tomino Y., Koide H. Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Renal. Physiol. Biochem. 1994, 17: 316-325.
40. Del Prete D., Anglani F., Forino M., Ceol M., Fioretto P., Nosadini R., Baggio B., Gambaro G. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 1997, 40: 1449-1454.
41. Kitamura M., Kitamura A., Mitarai T., Maruyama N., Nagasawa R., Kawamura T., Yoshida H., Takahashi T., Sakai O. Gene expression of metalloproteinase and its inhibitor in mesangial cells exposed to high glucose. Biochem. Biophys. Res. Commun. 1992, 185: 1048-1054.
42. Leehey D.J., Song R.H., Alavi N., Singh A.K. Decreased degradative enzymes in mesangial cells cultured in high glucose media. Diabetes 1995, 44: 929-935.
43. Wahab N., Mason R.M. Modulation of neutral protease expression in human mesangial cells by hyperglycemic cultures. Biochem. J. 1996, 320: 777-783.
44. Lubec G., Pollak A. Reduced susceptibility of nonenzymatically glucosylated glomerular basement membrane to proteases: is thickening of diabetic glomerular basement membranes due to reduced proteolytic degradation? Renal. Physiol. 1980, 3: 4-8.
45. Tarsio J.F., Reger L.A., Furcht L.T. Decreased interaction of fibronectin, type IV collagen and heparin due to nonenzymatic glycation. Implications for diabetes mellitus. Biochemistry 1987, 26: 1014-1020.
46. Tarsio J.F., Reger L.A., Furcht L.T. Molecular mechanisms in basement membrane complications in diabetes. Alterations in heparin, laminin and type IV collagen association. Diabetes 1988, 37: 532-539.
47. Cohen M.P., Saini R., Klepser H., Vasanthi L.G. Fibronectin binding to glomerular basement membrane is altered in diabetes. Diabetes 1987, 36: 758-763.
48. Steffes M.W., Bilous R.W., Sutherland D.E.R., Mauer S.M. Cell and matrix component of the glomerular mesangium in type I diabetes. Diabetes 1992, 41: 679-684.
49. Pabst R., Sterzel R.B. Cell renewal of glomerular cell types in normal rats. An autoradiographic analysis. Kidney Int. 1983, 24: 626-631.
50. Robertson H., Wheeler J., Morley A.R. In vivo bromodeoxyuridine incorporation in normal mouse kidney: immunohistochemical detection and measurement of labelling indices. Histochem J. 1990, 22: 209-214.
51. Fine L. The biology of renal hypertrophy. Kidney Int. 1986, 29: 619-634.
52. Beer D.G., Zweifel K.A., Simpson D.P., Pitot H.C. Specific gene expression during compensatory renal hypertrophy in the rat. J. Cell. Physiol. 1987, 131: 29-35.
53. Pesce C.M., Striker L.J., Peten E.P., Elliot S.J., Striker G.E. Glomerulosclerosis at both early and late stages is associated with increased cell turnover in mice transgenic for growth hormone. Lab. Invest. 1991, 65: 601-605.
54. Gambaro G., Venturini A.P., Noonan D.M., Fries W., Re G., Gerbisa S., Milanesi C., Pesarini A., Borsatti A., Marchi E., Baggio B. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int. 1994, 46: 797-806.
55. Young B.A., Johnson R.J., Alpers C.E., Eng E., Gordon K., Floege J., Couser W.G. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int. 1995, 47: 935-944.
56. Nakamura T., Fukui M., Ebihara I., Osada S., Nagaoka I., Tomino Y., Koide H. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993, 42: 450-456.
57. Wolf G., Schroeder R., Thaiss F., Ziyadeh F.N., Helmehen U., Stahl R.A. Glomerular expression of p27Kip1 in diabetic db/db mouse: role of hyperglycemia. Kidney Int. 1998, 53: 869-879.
58. Wolf G., Schroeder R., Ziyadeh F.N., Thaiss F., Zahner G., Stahl R.A. High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells: relationship to hypertrophy. Am. J. Physiol. 1997, 273: F348-F356.
59. Schwartzman R.A., Cidlowski J.A. Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocr. Rev. 1993, 14: 133-151.
60. Evan G.I., Brown L., Whyte M., Harrington E. Apoptosis and the cell cycle. Curr. Opin. Cell. Biol. 1995, 7: 825-834.
61. Baker A.J., Mooney A., Hughes J., Lombardi D., Johnson R.J., Savill J. Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J. Clin. Invest. 1994, 94: 2105-2116.
62. Shimizu A., Kitamura H., Masuda Y., Ishizaki M., Sugisaki Y., Yamanaka N. Apoptosis in the repair process of experimental proliferative glomerulonephritis. Kidney Int. 1995, 47: 114-121.
63. Savill J., Mooney A., Hughes J. Apoptosis and renal scarring. Kidney Int. 1996, 49: S14-S17.
64. Sugiyama H., Kashihara N., Makino H., Yamasaki Y., Ota Z. Apoptosis in glomerular sclerosis. Kidney Int. 1996, 49: 103-111.
65. Lieberthal W., Levine J.S. Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury. Am. J. Physiol. 1996, 277: F477-F488.
66. Zhang W., Khanna P., Chan L.L., Campbell G., Ansari N.H. Diabetes-induced apoptosis in rat kidney. Biochem. Mol. Med. 1997, 61: 58-62.
67. Ortiz A., Ziyadeh F.N., Neilson E.G. Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. J. Invest. Med. 1997, 45: 50-56.
68. Ishii N., Ogawa Z., Suzuki K., Numakami K., Saruta T., Itoh H. Glucose loading induces DNA fragmentation in rat proximal tubular cells. Metabolism 1996, 45: 1348-1353.
69. Gibbons G.H., Dzau V.J. The emerging concept of vascular remodeling. N. Engl. J. Med. 1994, 330: 1431-1438.
70. Frenette P.S., Wagner D.D. Molecular medicine. Adhesion molecules - Part I. N. Engl. J. Med. 1996, 334: 1526-1529.
71. Ruoslahti E., Obrink B. Common principles in cell adhesion. Exp. Cell. Res. 1996, 227: 1-11.
72. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., Border W.A. Expression of transforming growth factor-β is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA 1993, 90: 1814-1818.
73. Park L.-S., Kiyomoto H., Abboud S.L., Abboud H.E. Expression of transforming growth factor-β and type IV collagen in early streptozotocin-induced diabetes. Diabetes 1997, 46: 473-480.
74. Bollineni J.S., Reddi A.S. Transforming growth factor-β1 enhances glomerular collagen synthesis in diabetic rats. Diabetes 1993, 42: 1673-1677.
75. Shankland S.J., Scholey J.W. Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int. 1994, 46: 430-442.
76. Border W.A., Ruoslahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J. Clin. Invest. 1992, 90: 1-7.
77. Border W.A., Noble N.A. Transforming growth factor-β in tissue fibrosis. N. Engl. J. Med. 1994, 337: 1286-1292.
78. Border W.A., Okuda S., Languino L.R., Sporn M.B., Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 1990, 346: 371-374.
79. Border W.A., Noble N.A., Yamamoto T., Harper J.R., Yamaguchi S., Pierschbacher M.D., Ruoslahti E. Natural inhibitor of transforming growth factor B protects against scarring in experimental kidney disease. Nature 1992, 360: 361-364.
80. Isaka Y., Akagi Y., Ando Y., Tsujie M., Sudo T., Ohno N., Border W.A., Noble N.A., Kaneda Y., Hori M., Imai E. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. 1999, 55: 465-475.
81. Pankewycz O.G., Guan J.-X., Bolton W.K., Gomez A., Benedict J.F. Renal TGF-β regulation in spontaneously diabetic NOD mice with correlations in mesangial cells. Kidney Int. 1994, 46: 748-758.
82. Ziyadeh F.N., Sharma K., Ericksen M., Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β1. J. Clin. Invest. 1994, 93: 536-542.
83. Isaka Y., Fujiwara Y., Ueda N., Kaneda Y., Kamada T., Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J. Clin. Invest. 1993, 92: 2597-2601.
84. Sanderson N., Factor V.M., Nagy P., Kopp J., Kondaiah P., Wakefield L., Roberst A.B., Spom M.B., Thorgeirsson S.S. Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc. Natl. Acad. Sci. USA 1995, 92: 2572-2576.
85. Kopp J., Factor V.M., Mozes M., Nagy P., Sanderson N., Bottinger E.P., Klotman P.E., Thorgeirsson S.S. Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab. Invest. 1996, 74: 991-1003.
86. Ignotz R.A., Massaguè J. Transforming growth factor β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem. 1986, 261: 4337-4345.
87. Bassols A., Massaguè J. Transforming growth factor β regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. J. Biol. Chem. 1988, 263: 3039-3045.
88. Roberts C.J., Birkenmeier T.M., McQuillan J.J., Akiyaqma S.K., Yamada S.S., Chen W.-T., Yamada K.M., McDonald J.A. Transforming growth factor β stimulates the expression of fibronectin and of both subunits of the human fibronectin receptor by cultured human lung fibroblasts. J. Biol. Chem. 1988, 263: 4586-4592.
89. Heino J., Ignotz R.A., Hemler M.E., Crouse C., Massaguè J. Regulation of cell adhesion receptors by transforming growth factor-β: concomitant regulation of integrins that share a common β1 subunit. J. Biol. Chem. 1989, 264: 380-388.
90. Border W.A., Okuda S., Languino L.R., Ruoslahti E. Transforming growth factor-β regulates production of proteoglycans by mesangial cells. Kidney Int. 1990, 37: 689-695.
91. Creely J.J., DiMari S.J., Howe A.M., Haralson M.A. Effects of transforming growth factor-β on collagen synthesis by normal rat kidney epithelial cells. Am. J. Pathol. 1992, 140: 45-55.
92. Pricci F., Pugliese G., Romano G., Romeo G., Locuratolo N., Menè P., Pugliese F., Galli G., Casini A., Rotella C.M., Di Mario U. Insulin-like growth factor (IGF)-I and IGF-II stimulate extracellular matrix production in human mesangial cells. Comparison with transforming growth factor-β (TGF-β). Endocrinology 1996, 137: 879-885.
93. Tomooka S., Border W.A., Ruoslahti E., Noble W.A. Glomerular matrix accumulation is linked to inhibition of plasmin protease system. Kidney Int. 1992, 42: 1462-1469.
94. Choi M.E., Kim E.-G., Huang Q., Ballermann B.J. Rat mesangial cell hypertrophy in response to transforming growth factor-β1. Kidney Int. 1993, 44: 948-958.
95. Battegay E.J., Raines E.W., Seifert R.A., Bowen-Pope D.F., Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990, 63: 515-524.
96. Okuda S., Languino L.R., Ruoslahti E., Border W.A. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J. Clin. Invest. 1990, 86: 453-462.
97. Hoffman B.B., Sharma K., Zhu Y., Ziyadeh F.N. Transcriptional activation of transforming growth factor-β1 in mesangial cells culture by high glucose concentration. Kidney Int. 1998, 54: 1107-1116.
98. Border W.A., Noble N.A. Interactions of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension 1998, 31 (Part 2): 181-188.
99. Gibbons G.H., Pratt R.E., Dzau V.J. Vascular smooth muscle cell hypertrophy vs hyperplasia: autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J. Clin. Invest. 1992, 90: 456-461.
100. Kagami S., Border W.A., Mille D.E., Noble N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat mesangial cells. J. Clin. Invest. 1994, 93: 2431-2437.
101. Noble N.A., Border W.A. Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target? Semin. Nephrol. 1997, 17: 455-466.
102. Ohno M., Cooke J.P., Dzau V.J., Gibbons G.H. Fluid shear stress induces endothelial transforming growth factor-β transcription and production. J. Clin. Invest. 1997, 95: 1363-1369.
103. Peters H., Border W.A., Noble N.A. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int. 1998, 54: 1570-1580.
104. Horikoshi S., McCune B.K., Ray P.E., Kopp J.B., Klotman P.E. Water deprivation stimulates transforming growth factor-β2 accumulation in the iuxtaglomerular apparatus of mouse kidney. J. Clin. Invest. 1992, 88: 2117-2122.
105. Ray P.E., McCune B.K., Gomez R.A., Horikoshi S., Kopp J.B., Klotman P.E. Renal vascular induction of TGF-β2 and renin by potassium depletion. Kidney Int. 1993, 44: 1006-1013.
106. Veniant M., Menard J., Bruneval P., Morley S., Gonzales M.F., Mullins J. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J. Clin. Invest. 1966, 98: 1996-1970.
107. Greene E.L., Kren S., HostetterT.H. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 1996, 98: 1063-1068.
108. Feige J.J., Cochet C., Rainey W.E., Mandani C., Chambaz E.M. Type b transforming growth factor affects adrenocortical cell-differential functions. J. Biol. Chem. 1987, 262: 13491-13495.
109. Gupta P., Franco-Saenz R., Gentry L.E., Mulrow P.J. Transforming growth factor β1 inhibits aldosterone and stimulates adrenal renin in cultured bovine zona glomerulosa cells. Endocrinology 1992, 131: 631-636.
110. Husted R.F., Matsushita K., Stokes J.B. Induction of resistance to mineralocorticoid hormone in cultured inner medullary collecting duct cells by TGF-β1. Am. J. Physiol. 1994, 267: F767-F775.
111. Flyvbjerg A., Thorlacius-Ussing O., Naeraa R., Ingerslev J., Ørskov H. Kidney tissue somatomedin C and initial renal growth in diabetic and uninephrectomized rats. Diabetologia 1988, 31: 310-314.
112. Bach L.A., Jerums G. Effect of puberty on initial kidney growth and rise in kidney IGF-I in diabetic rats. Diabetes 1990, 39: 557-562.
113. Flyvbjerg A., Frystyk J., Marshall M. Additive increase in kidney insulin-like growth factor I and initial renal enlargement in uninephrectomized-diabetic rats. Horm. Metab. Res. 1990, 22: 516-520.
114. Flyvbjerg A., Bornfeldt K.E., Marshall S.M., Arnqvist H.J., Ørskov H. Kidney IGF-1 mRNA in initial renal hypertrophy in experimental diabetes in rats. Diabetologia 1990, 33: 334-338.
115. Marshall S.M., Flyvbjerg A., Frystyk J., Korsgaard L., Ørskov H. Renal insulin-like growth factor I and growth hormone receptor binding in experimental diabetes and after unilateral nephrectomy in the rat. Diabetologia 1991, 34: 632-639.
116. Werner H., Shen-Orr Z., Stannard B., Burguera B., Roberts C.T. Jr., LeRoith D. Experimental diabetes increases insulin-like growth factor I and II receptor concentration and gene expression in kidney. Diabetes 1990, 39: 1490-1497.
117. Bach L.A., Stevenson J.L., Allen T.J., Jerums G., Herington A.C. Kidney insulin-like growth factor I mRNA levels are increased in postpubertal diabetic rats. J. Endocrinol. 1991, 129: 5-10.
118. Catanese V.M., Sciavolino P.J., Lango M.N. Discordant, organ-specific regulation of insulin-like growth factor-I messenger ribonucleic acid in insulin-deficient diabetic rats. Endocrinology 1993, 132: 496-503.
119. Graubert M.D., Goldstein S., Phillips L.S. Nutrition and somatomedin. XXVII. Total and free IGF-I and IGF binding proteins in rats with streptozotocin induced diabetes. Diabetes 1991, 40: 959-965.
120. Flyvbjerg A., Kessler U., Dorka B., Funk B., Ørskov H., Kiess W. Transient increase in renal insulin-like growth factor binding proteins during initial renal hypertrophy in experimental diabetes in rats. Diabetologia 1992, 35: 589-593.
121. Gelato M.C., Alexander D.A., Marsh K. Differential tissue regulation of insulin-like growth factor binding proteins in experimental diabetes mellitus in the rat. Diabetes 1992, 41: 1511-1519.
122. Ooi G.T., Tseng L.Y.-H., Tran M.Q., Rechler M. Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol. Endocrinol. 1992, 6: 2219-2228.
123. Clemmons D.R. IGF binding proteins and their functions. Mol. Reprod. Dev. 1993, 35: 368-375.
124. Landau D., Chin E., Bondy C., Domene H., Roberts C.T. Jr, Gronbaek H., Flyvbjerg A., LeRoith D. Expression of insulin-like growth factor-binding proteins in the rat kidney: effects of long-term diabetes. Endocrinology 1995, 136: 1835-1842.
125. Cohick W.S., Clemmons D.R. The insulin-like growth factors. Annu. Rev. Physiol. 1993, 55: 131-153.
126. Hammerman M.R., Miller S.B. The growth hormone insulin-like growth factor axis in kidney revisited. Am. J. Physiol. 1993, 265: F1-F14.
127. Doi T., Hattori M., Agodoa L.Y., Sato T., Yoshida H., Striker L.J., Striker G.E. Glomerular lesions in nonobese diabetic mouse: before and after the onset of hyperglycemia. Lab. Invest. 1990, 63: 204-212.
128. Elliot S.J., Striker L.J., Hattori M., Yang C.-W., He C.-J., Peten E.P., Striker G.E. Mesangial cells from diabetic NOD mice constitutively secrete increased amounts of insulin-like growth factor I. Endocrinology 1993, 133: 1783-1788.
129. Oemar B.S., Foellmer H.G., Hodgdon-Anandant L., Rosenzweig S.A. Regulation of insulin-like growth factor I receptors in diabetic mesangial cells. J. Biol. Chem. 1991, 266: 2369-2373.
130. Doi T., Striker L.J., Elliot S.J., Conti F.G., Striker G.E. Insulin-like growth factor-1 is a progression factor for human mesangial cells. Am. J. Pathol. 1989, 134: 395-404.
131. 1 progression and protein modification by SmC/IGF I. Am. J. Physiol. 1987, 253: C575-C579.
132. Moran A., Brown D.M., Kim Y., Klein D.J. Effects of IGF-I and glucose on protein and proteoglycan synthesis by human fetal mesangial cells in culture. Diabetes 1991, 40: 1346-1354.
133. Watanabe Y., Kashihara N., Makino H., Kanwar Y.S. Modulation of glomerular proteoglycans by insulin-like growth factor-1. Kidney Int. 1992, 41: 1262-1273.
134. Tamaroglio T.A., Lo C.S. Regulation of fibronectin by insulin-like growth factor-I in cultured rat thoracic aortic smooth muscle cells and glomerular mesangial cells. Exp. Cell Res. 1994, 215: 338-346.
135. Hirschberg R., Kopple J.D. Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats. J. Clin. Invest. 1989, 83: 326-330.
136. Hirschberg R., Kopple J.D., Blantz R.C., Tucker B.J. Effects of recombinant human insulin-like growth factor I on glomerular dynamics in the rat. J. Clin. Invest. 1991, 87: 1200-1206.
137. Doi T., Striker L.J., Quaife C., Conti F.G., Palmiter R., Behringer R., Brinster R.L., Striker G.E. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulin like growth factor-I. Am. J. Pathol. 1988, 131: 398-403.
138. Doi T., Striker L.J., Kimata K., Peten E.P., Yamada Y., Striker G.E. Glomerulosclerosis in mice transgenic for growth hormone increased mesangial extracellular matrix is correlated with kidney mRNA levels. J. Exp. Med. 1991, 173: 1287-1290.
139. Jacot T.A., Striker G.E., Stetler-Stevenson M., Striker L.J. Mesangial cells from transgenic mice with progressive glomerulosclerosis exhibit stable, phenotypic changes including undetectable MMP-9 and increased type IV collagen. Lab. Invest. 1996, 75: 791-799.
140. Kjeldsen H., Hansen P., Lundbaek K. Twenty-four hour serum growth hormone levels in maturity onset diabetes. Diabetes 1995, 24: 977-982.
141. Hirschberg R., Kopple J.D. Effects of growth hormone on GFR and renal plasma flow in man. Kidney Int. 1987, 32 (Suppl. 22): S21-S24.
142. Pedersen M.M., Christensen S.E., Christiansen J.S., Pedersen E.B., Mogensen C.E., Ørskov H. Acute effects of a somatostatin analogue on kidney function in type I diabetic patients. Diabetic Med. 1990, 7: 304-309.
143. Stegeman C.A., Dullaart R.P.F., Meijer S., Marbach P., Sluiter W.J. Acute renal effects of somatostatin analogue, octreotide, in insulin-dependent diabetic patients: antagonism by low dose glucagon. Diab. Nutr. Metab. 1993, 6: 87-95.
144. Tannenbaum G.S. Growth hormone secretory dynamics in streptozotocin diabetes: evidence of a role for exogenous circulating somatostatin. Endocrinology 1981, 108: 76-82.
145. Bornfeldt K.E., Arnquist H.J., Enberg B., Mathews L.S., Norstedt G. Regulation of insulin-like growth factor I and growth hormone receptor gene expression by diabetes and nutritional state in rat tissues. J. Endocrinol. 1989, 122: 651-656.
146. Flyvbjerg A., Frystyk J., Thorlacius-Ussing O., Ørskov H. Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats. Diabetologia 1989, 32: 261-265.
147. Gronbæk H., Nielsen B., Frystyck J., Flyvbjerg A., Ørskov H. Effect of lanreotide, a somatostatin analogue, on diabetic renal hypertrophy, kidney and serum IGF-I and IGF-binding proteins. Exp. Nephrol. 1996, 4: 295-303.
148. Flyvbjerg A., Marshall S.M., Frystyk J., Hansen K.W., Harris A.G., Ørskov H. Octreotide administration in diabetic rats: effects on renal hypertrophy and urinary albumin excretion. Kidney Int. 1992, 41: 805-812.
149. Flyvbjerg A., Bennet W.F., Rash R., Kopchick J.J., Scarlett J.A. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy and urinary albumin excretion in experimental diabetes in mice. Diabetes 1999, 48: 377-382.
150. Flyvbjerg A., Frystyk J., Østerby R., Ørskov H. Kidney IGF-I and renal hypertrophy in GH-deficient diabetic dwarf rats. Am. J. Physiol. 1992, 262: E956-E962.
151. Chen N.Y., Chen W.Y., Bellush L.,Yang C.W., Striker L.J., Striker G.E., Kopchick J.J. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 1995, 136: 660-667.
152. Esposito C., Liu Z.H., Striker G.E., Phillips C., Chen N.Y., Chen W.Y., Kopchick J.J., Striker L.J. Inhibition of diabetic nephropathy by a GH antagonist: a molecular analysis. Kidney Int. 1996, 50: 506-514.
153. Yang C.W., Striker G.E., Chen W.Y., Kopchick J.J., Striker L.J. Differential expression of glomerular extracellular matrix and growth factor mRNA in rapid and slowly progressive glomerulosclerosis: studies in mice transgenic for native or mutated growth hormone. Lab. Invest. 1997, 76: 467-476.
154. Stout R.W. Hyperinsulinemia and atherosclerosis. Diabetes 1996, 45 (Suppl. 3): S45-S46.
155. Anderson P.W., Zhang X.Y., Tian J., Correale J.D., Xi X.P., Yang D., Graf K., Law R.E., Hsueh W.A. Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells. Kidney Int. 1996, 50: 745-753.
156. Pandolfi A., Iacoviello L., Capani F., Vitacolonna E., Donati M.B., Consoli A. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabetologia 1996, 39: 1425-1431.
157. Schmetterer L., Muller M., Fasching P., Diepolder C., Gallenkamp A., Zanaschka G., Findl O., Strenn K., Mensik C., Tschernko E., Eichler H.G., Wolzt M. Renal and ocular hemodynamic effects of insulin. Diabetes 1997, 46: 1868-1874.
158. Fagerudd J.A., Groop P.H., Honkanen E., Teppo A.M., Gronhangen-Riska C. Urinary excretion of TGF-beta 1, PDGF-BB and fibronectin in insulin-dependent diabetes mellitus patients. Kidney Int. 1997, 63: S195-S197.
159. Gesualdo L., Pinzani M., Floriano J.J., Hassan M.O., Nagy N.U., Schena F.P., Emancipator S.N., Abboud H.E. Platelet-derived growth factor expression in mesangial proliferative glomerulonephritis. Lab. Invest. 1991, 65: 160-167.
160. Gesualdo I., Di Paolo S., Milani S., Pinzani M., Grappone C., Ranieri E., Pannarale G., Schena F.P. Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study. J. Clin. Invest. 1994, 94: 50-58.
161. Di Paolo S., Gesualdo L., Ranieri E., Grandaliano G., Schena F.P. High glucose concentrations induce the overexpression of transforming growth factor-beta through the activation of a platelet-derived growth factor loop in human mesangial cells. Am. J. Pathol. 1996, 149: 2095-2106.
162. Phillips A.O., Steadman R., Topley N., Williams J.D. Elevated D-glucose concentrations modulate TGF-beta 1 synthesis by human cultured renal proximal tubular cells. The permissive role of platelet-derived growth factor. Am. J. Pathol. 1995, 147: 362-374.
163. Floege J., Eng E., Young B.A., Alpers C.E., Barrett T.B., Bowen-Pope D.F., Johnson R.J. Infusion of platelet-derived growth factor and basic fibroblast growth factor induces selective glomerular messangial cell proliferation and matrix accumulation in rats. J. Clin. Invest. 1993, 92: 2952-2962.
164. Johnson R.J., Raines E., Floege J., Yoshimura A., Protzl P., Alpers C.E., Ross R. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J. Exp. Med. 1992, 175: 1413-1416.
165. Shultz P.J., Di Corleto P.E., Silver B.J., Abboud H.E. Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am. J. Physiol. 1988, 255: F674-F679.
166. Doi T., Vlassara H., Kirstein M., Yamada Y., Striker G.E., Striker L.J. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc. Natl. Acad. Sci. USA 1992, 89: 2873-2887.
167. Floege J., Eng E., Lindner V., Young B.A., Reidy M.A., Johnson R.J. Rat glomerular mesangial cells synthesize basic FGF: release, upregulated synthesis and mitogenicity in mesangial proliferative glomerulonephritis. J. Clin. Invest. 1992, 90: 2362-2369.
168. Battegay E.J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med. 1995, 73: 333-346.
169. Miller S.B., Rogers S.A., Estes C.E., Hammerman M.R. Increased distal nephron EGF content and altered distribution of peptide in compensatory renal hypertrophy. Am. J. Physiol. 1992, 262: F1032-F1038.
170. Hwang D.L., Lev-Ran A. Epidermal growth factor in serum, urine, submandibular glands and kidneys of diabetic mice. Life Sci. 1990, 47: 679-685.
171. Hwang D.L., Lev-Ran A., Tay Y.C., Chen C.R, Dev N. Epidermal growth factor excretion and receptor binding in diabetic rats. Life Sci. 1989, 44: 407-416.
172. Kawaguchi M., Kamiya Y., Ito J., Fuji T., Hayakawa F., Sakuma N., Fujinami T. Excretion of epidermal growth factor in non-insulin dependent diabetes mellitus. Life Sci. 1993, 52: 1181-1186.
173. Mattila A.-L., Pasternack A., Viinika L., Perheentupa J. Subnormal concentrations of urinary epidermal growth factor in patients with kidney disease. J. Clin. Endocrinol. Metab. 1986, 62: 1180-1183.
174. Williams B. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy? Miner. Electrolyte Metab. 1998, 24: 400-405.
175. Grone H.J., Simon M., Grone E.F. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J. Pathol. 1995, 177: 259-267.
176. Wasada T., Kawahara R., Katsumori K., Naruse M., Omori Y. Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism 1998, 47: 27-30.
177. Ferrara N., Davis-Smith T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18: 4-25.
178. Trachman H., Futterweit S., Franki N., Singhal P.C. Effect of vascular endothelial growth factor on nitric oxide production by cultured rat mesangial cells. Biochem. Biophys. Res. Commun. 1998, 245: 443-446.
179. Fukui M., Nakamura T., Ebihara I., Osada S., Tomino Y., Masaki T., Goto K., Furuiki Y., Koide H. Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J. Lab. Clin. Med. 1993, 122: 149-156.
180. Fukui M., Nakamura T., Ebihara I., Makita Y., Osada S., Tomino Y., Koide H. Effects of enalapril on endothelin-1 and growth factor gene expression in diabetic rat glomeruli. J. Lab. Clin. Med. 1994, 123: 763-768.
181. Shin S.J., Lee Y.J., Lin S.R., Tan M.S., Lai Y.M., Tsai J.M. Decrease of renal endothelin 1 content and gene expression in diabetic rats with moderate hyperglycemia. Nephron. 1995, 70: 486-493.
182. Lam H.C., Lee J.K., Chiang H.T., Koh S.J., Han T.M., Lu C.C., Yang C.Y., Hao L.J. Does endothelin play a role in the pathogenesis of early diabetic nephropathy. J. Cardiovasc. Pharmacol. 1995, 26: S479-S481.
183. Lee Y.J., Shin S.J., Tsai J.M. Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria Diabetes Care 1994, 17: 263-266.
184. De Mattia G., Cassone-Faldetta M., Bellini C., Bravi M.C., Laurenti O., Baldoncini R., Santucci A., Ferri C. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am. J. Hypertens. 1998, 11: 983-988.
185. Gomez-Garre D., Ruiz-Ortega M., Ortego M., Largo R., Lopez-Armada M.J., Plaza J.J., Gonzalez E., Egido J. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996, 27: 885-892.
186. Hocher B., Lun A., Priem F., Neumayer H.H., Raschack M. Renal endothelin system in diabetes: comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism. J. Cardiovasc. Pharmacol. 1998, 31: S492-S495.
187. Nakamura T., Ebihara I., Tomino Y., Koide H. Alteration of growth-related proto-oncogene expression in diabetic glomeruli by a specific endothelin receptor A antagonist. Nephrol. Dial. Transplant. 1996, 11: 1528-1531.
188. Benigni A., Colosio V., Brena C., Bruzzi I., Bertani T., Remuzzi G. Unselective inhibition of endothelin receptor reduces renal dysfunction in experimental diabetes. Diabetes 1998, 47: 450-456.
189. Lin S., Chen J., Zhu W. Existence of an abnormal nitric oxide metabolism seen in glomeruli and inner medullary collecting duct in diabetic rat. Chin. Med. J. 1997, 110: 515-519.
190. Komers R., Allen T.J., Cooper M.E. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 1994, 43: 1190-1197.
191. Sugimoto H., Shikata K., Matsuda M., Kushiro M., Hayashi Y., Hiragushi K., Wada J., Makino H. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic rats. Diabetologia 1998, 41: 1426-1434.
192. Choi K.C., Lee S.C., Kim S.W., Kim N.H., Lee J.U., Kang Y.J. Role of nitric oxide in the pathogenesis of diabetic nephropathy in streptozotocin-induced diabetic rats. Korean J. Int. Med. 1999, 14: 32-41.
193. Trachtman H., Futterweit S., Crimmins D.L. High glucose inhibits nitric oxide production by cultured rat mesangial cells. J. Am. Soc. Nephrol. 1997, 8: 1276-1282.
194. Trachtman H., Koss I., Bogart M., Abramowitz J., Futterweit S., Franki N., Singhai P.C. High glucose enhances growth factor-stimulated nitric oxide production by cultured rat mesangial cells. Res. Commun. Mol. Pathol. Pharmacol. 1998, 100: 213-225.
195. Amore A., Cirina P., Mitola S., Peruzzi L., Gianoglio B., Rabbone I., Sacchetti C., Cerutti F., Grillo C., Coppo R. Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells. Kidney Int. 1997, 51: 27-35.
196. Wessels J., Peake P., Pussel B.A., Macdonald G.J. Nitric oxide inhibition in a spontaneously hypertensive rat model of diabetic nephropathy. Clin. Exp. Pharmacol. Physiol. 1997, 24: 451-453.
197. Soulis T., Cooper M.E., Sastra S., Thallas V., Panagiotopulos S., Bjerrum O.J., Jerums G. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 1997, 40: 1141-1151.
198. Lubec B., Aufricht C., Amann G., Kitzmuller E., Hoger H. Arginine reduces kidney collagen accumulation, crosslinking, lipid peroxidation, glycoxidation, kidney weight and albuminuria in the diabetic kk mouse. Nephron 1997, 75: 213-218.
199. Williams B., Schrier R.W. Glucose-induced protein kinase C activity regulates arachidonic acid release and prostaglandin production by cultured rat mesangial cells. J. Clin. Invest. 1993, 92: 2889-2896.
200. Kreisberg J.I., Patel P.Y. The effects of insulin, glucose and diabetes on prostaglandin production by rat kidney glomeruli and cultured glomerular mesangial cells. Prostaglandis Leukot Med. 1983, 11: 431-442.
201. Pricci F., Pugliese G., Menè P., Romeo G., Romano G., Galli G., Casini A., Rotella C.M., Di Mario U., Pugliese F. Regulatory role of eicosanoids in extracellular matrix overproduction induced by prolonged exposure to high glucose concentrations in cultured rat mesangial cells. Diabetologia 1996, 39: 1055-1062.
202. Craven P.A., Caines M.A., DeRubertis F.R. Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: relationship to the hyperfiltration of early diabetes. Metabolism 1987, 36: 95-103.
203. 2 on mRNA expression and secretion of collagen I, III, and IV and fibronectin in cultured rat mesangial cells. J. Am. Soc. Nephrol. 1994, 4: 1778-1785.
204. Bruggeman L.A., Pellicoro J.A., Horigan E.H., Klotman P.E. Thromboxane and prostacyclin differentially regulate murine extracellular matrix gene expression. Kidney Int. 1993, 43: 1219-1225.
205. 2 on transforming growth factor-β and insulin-induced collagen formation in lung fibroblasts. J. Biol. Chem. 1989, 29: 16988-16991.
206. Ledbetter S., Copeland E.J., Noonan D., Vogeli G., Hassell J.R. Altered steady-state mRNA levels of basement membrane proteins in diabetic mouse kidneys and thromboxane synthase inhibition. Diabetes 1990, 39: 196-203.
207. Juhan-Vague I., Alessi M.C., Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann. Med. 1996, 28: 371-380.
208. Rondeau E., Mougenot B., Lacave R., Peraldi M.N., Kruithof E.K., Sraer J.D. Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. Clin. Nephrol. 1990, 33: 55-60.
209. Yamamoto T., Noble N.A., Cohen A.M., Nast C.C., Hishida A., Gold L.I., Border W.A. Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int. 1996, 49: 461-469.
210. Tomooka S., Border W.A., Marshall B.C., Noble N.A. Glomerular matrix accumulation is linked to inhibition of plasmin protease system. Kidney Int. 1992, 42: 1462-1469.
211. Loskutoff D.J., Sawdey M., Keeton M., Schneiderman J. Regulation of PAI-1 gene expression in vivo. Thromb. Haemost. 1993, 70: 135-137.
212. Feng L., Tang W.W., Loskutoff D.J., Wilson C.B. Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis. J. Am. Soc. Nephrol. 1993, 3: 1753-1764.
213. Fisher E.J., McLennan S.V., Yue D.K., Turtle J.R. High glucose reduces generation of plasmin activity by mesangial cells. Microvasc. Res. 1997, 53: 173-178.
214. Oikawa T., Freeman M., Lo W., Vaughan D.E., Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 1997, 51: 164-172.
215. Kagami S., Kuhara T., Okada K., Kuroda Y., Border W.A., Noble N.A. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int. 1997, 51: 664-671.
216. Eitzman D.T., McCoy R.D., Zheng X., Fay W.P., Shen T, Ginsburg D., Simon R.H. Bleomycin induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 1996, 97: 232-237.
217. Baricos W.H., Cortez S.L., el-Dahr S.S., Schnaper H.W. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int. 1995, 47: 1039-1047.
218. Jin D.K., Fish A.J., Wayner E.A., Mauer M., Setty S., Tsillabary E., Kim Y. Distribution of integrin subunits in human diabetic kidneys. J. Am. Soc. Nephrol. 1996, 7: 2636-2645.
219. Regoli M., Bendayan M. Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia 1997, 40: 15-22.
220. Roth T., Podestà F., Stepp M.A., Boeri D., Lorenzi M. Integrin overexpression induced by high glucose and by human diabetes: potential pathway to cell dysfunction in diabetic microangiopathy. Proc. Natl. Acad. Sci. USA 1993, 90: 9640-9644.
221. Hirata K., Shikata K., Matsuda M., Akiyama K., Sugimoto H., Kushiro M., Makino H. Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia 1998, 41: 185-192.
222. Knudsen H., Andersen C.B., Ladefoged S.D. Expression of the intercellular adhesion molecule-3 (ICAM-3) in human renal tissue with relation to kidney transplant and various inflammatory diseases. APMIS 1995, 103: 593-596.
223. Matsui H., Suzuki M., Tsukuda R., Iida K., Miyasaka M., Ikeda H. Expression of ICAM-1 on glomeruli is associated with progression of diabetic nephropathy in a genetically-obese diabetic rat, Wistar fatty. Diabetes Res. Clin. Pract. 1996, 32: 1-9.
224. Seron D., Cameron J.S., Haskard D.O. Expression of VCAM-1 in the normal and diseased kidney. Nephrol. Dial. Transplant 1991, 6: 917-922.
225. Keogh R.J., Dunlop M.E., Larkins R.G. Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation. Metabolism 1997, 46: 41-47.
226. Ishii H., Tada H., Isogai S. An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured mesangial cells. Diabetologia 1998, 41: 362-364.
227. Daniels B.S., Hostetter T.H. Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes 1989, 38: 981-986.
228. Kikkawa R., Umemura K., Haneda M., Arimura T., Ebata K., Shigeta Y. Evidence for existence of polyol pathway in cultured rat mesangial cells. Diabetes 1987, 36: 240-243.
229. Shah V.O., Dorin R.I., Sun Y., Braun M., Zager P.G. Aldose reductase gene expression is increased in diabetic nephropathy. J. Clin. Endocrinol. Metab. 1997, 82: 2294-2298.
230. Shah V.O., Scavini M., Nikolic J., Sun Y., Vai S., Griffith J.K., Dorin R.I., Stidley C., Yacoub M., Vander Jagt D.L., Eaton R.P., Zager P.G. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J. Clin. Endocrinol. Metab. 1998, 83: 2886-2891.
231. Bank N., Mower P., Aynedjian H.S., Wilkes B.M., Silverman S. Sorbinil prevents glomerular hyperperfusion in diabetic rats. Am. J. Physiol. 1989, 256: F1000-1006.
232. Tilton R.G., Chang K., Pugliese G., Eades D.M., Province M.A., Sherman W.R., Kilo C., Williamson J.R. Prevention of hemodynamic and vascular (albumin) filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 1989, 38: 1258-1270.
233. Pugliese G., Tilton R.G., Speedy A., Chang K., Province M.A., Kilo C., Williamson J.R. Vascular filtration function in galactose-fed versus diabetic rats: the role of polyol pathway activity. Metabolism 1990, 39: 690-697.
234. Donnelly S.M., Zhou X.P., Huang J.T., Whiteside C.I. Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat. Biochem. Cell Biol. 1996, 74: 355-362.
235. Tilton R.G., Kawamura T., Chang K.C., Ido Y., Bjercke R.J., Stephan C.C., Brock T.A., Williamson J.R. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J. Clin. Invest. 1997, 99: 2192-2202.
236. Mauer S.M., Steffes M.W., Azar S., Brown D.M. Effects of sorbinil on glomerular structure and function in long-term diabetic rats. Diabetes 1989, 38: 839-846.
237. Tilton R.G., Pugliese G., LaRose L.S., Faller A.M., Chang K., Province M.A., Williamson J.R. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats. J. Diab. Compl. 1991, 5: 230-237.
238. Das B., Srivastava S.K. Activation of aldose reductase in human tissues. Diabetes 1985, 1145-1151.
239. Lorenzi M., Toledo S., Boss G.R., Lane M.J., Montisano D.F. The polyol pathway and glucose-6-phosphate in human endotelial cells cultured in high glucose concentrations. Diabetologia 1987, 30: 222-227.
240. Grahary A., Luo J., Gong Y. ,Chakrabarti S., Sima A.A.F. Increased renal aldose reductase activity, immuno-reactivity, and mRNA in streptozotocin-induced diabetic rats. Diabetes 1989, 38: 1067-1071.
241. McClain D.A., Crook E.D. Hexosamines and insulin resistance. Diabetes 1996, 45: 1003-1009.
242. Kolm-Litty V., Sauer U., Nerlich A., Lehmann R., Schleicher E.D. High glucose-induced transforming growth factor-β1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest. 1998, 101: 160-169.
243. Hebert L.J., Daniels M.C., Zhou J., Crook E.D., Tumer R.L, Simmons S.T., Neidigh J.L., Zhu J.S. Baron A.D., McClain D.A. Overexpression of glutamine-fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J. Clin. Invest. 1996, 98: 930-936.
244. Kolm-Litty V., Tippmer S., Haring H.U., Schleicher E. Glucosamine induces translocation of protein kinase C isoenzymes in mesangial cells. Exp. Clin. Endocrinol. Diabetes 1998, 106: 377-383.
245. Filippis A., Clark S., Proietto J. Increased flux through the hexosamine biosynthesis pathway inhibits glucose transport acutely by activation of protein kinase C. Biochem. J. 1997, 324: 981-985.
246. Roos M.D., Han I.O., Paterson A.J., Kudlow J.E. Role of glucosamine synthesis in the stimulation of TGF-α gene transcription by glucose and EGF. Am. J. Physiol. 1996, 270: C803-C811.
247. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47; 859-866.
248. Brawn M.K., Chiou W.J., Leach K.L. Oxidant-induced activation of protein kinase C in UC11MG cells. Free Radic. Res. 1995, 22: 23-37.
249. Kaul N., Gopalakrishna R., Gundimeda U., Choi J., Forman H.J. Role of protein kinase C in basal and hydrogen peroxide-stimulated NF-kappa B activation in the murine macrophage J774A.1 cell line. Arch. Biochem. Biophys. 1998, 350: 79-86.
250. Vlassara H. Protein glycation in the kidney: role in diabetes and aging. Kidney Int. 1996, 49: 1785-1804.
251. Craven P.A., DeRubertis F.R. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: possible mediation by glucose. J. Clin. Invest. 1989, 83: 1667-1675.
252. Craven P.A., Davidson C.M., DeRubertis F.R. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 1990, 39: 667-674.
253. Ayo S.H., Radnik R.A., Garoni J.A., Troyer D.A., Kreisberg J.I. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am. J. Physiol. 1991, 267: F571-577.
254. Haneda M., Araki S., Togawa M., Sugimoto T., Isono M., Kikkawa R. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997, 46: 847-853.
255. 1(IV) transcriptional activity in a reporter mesangial cell line. Am. J. Physiol. 1994, 267: F632-F638.
256. Studer R.K., Craven P.A., DeRubertis F.R. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high glucose medium. Diabetes 1993, 42: 118-126.
257. Koya D., Jirousek M.R., Lin Y.W., Ishii H., Kuboki K., King G.L. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. 1997, 100: 115-126.
258. Ishii H., Jirousek M.R., Koya D., Takagi C., Xia P., Clermont A., Bursell S.-E., Kern T.S., Ballas L.M., Heath W.F., Stramm L.E., Feener E.P., King G.L. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996, 272: 728-731.
259. Brownlee M., Cerami A., Vlassara H. Advanced glycation end-products in tissue and the biochemical bases of diabetic complications. N. Engl. J. Med. 1988, 318: 1315-1318.
260. Mullarkey C.J., Edelstein D., Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem. Biophys. Res. Commun. 1990, 173: 932-9.
261. Vlassara H., Bucala R., Striker L.J. Pathogenic effects of advanced glycosylation: biochemical, biological, and clinical implications for diabetes and aging. Lab. Invest. 1994, 70: 138-151.
262. Miyata S., Monnier V. Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. J. Clin. Invest. 1992, 89: 1102-1112.
263. Makita Z., Vlassara H., Cerami A., Bucala R. Immunochemical detection of advanced glycosylation endproducts in vivo. J. Biol. Chem. 1992, 267: 5133-5138.
264. He C.-J., Stitt A., Striker L.J., Hattori M., Vlassara H. Low expression of AGE-receptor-1 in NOD mouse mesangial cells: possible link to diabetic nephropathy. J. Am. Soc. Nephrol. 1996, 7: 1871A.
265. Leto G., Pricci F., Romeo G., Catalano S., Amadio L., Diaz-Horta O., Sale P., Gradini R., Lenti L., Barsotti P., Frigeri L., Di Mario U., Pugliese G. Induction of glomerular/mesangial galectin-3/AGE-receptor-3 expression by the diabetic milieu. Diabetologia 1998, 41 (Suppl. 1): A27.
266. Vlassara H., Striker L.J., Teichberg S., Fuh H., Li Y.M., Steffes M.W. Advanced glycation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. USA 1994, 91: 11704-11708.
267. Yang C.-W., Vlassara H., Peten E.P., He C.-J., Striker G.E., Striker L.J. Advanced glycation endproducts up-regulate gene expression found in diabetic glomerular disease. Proc. Natl. Acad. Sci. USA 1994, 91: 9436-9440.
268. Skolnik E., Yang Z., Makita Z., Radoff S., Kirstein M., Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J. Exp. Med. 1991, 174: 931-939.
269. Crowley S.T., Brownlee M., Edelstein D., Satriano J.A., Mori T., Singhal P.C., Schlondorff D.O. Effects of nonenzymatic glycosylation of mesangial matrix on proliferation of mesangial cells. Diabetes 1991, 40: 540-547.
270. Pugliese G., Pricci F., Romeo G., Menè P., Pugliese F., Giannini S., Cresci B., Galli G., Rotella C.M., Vlassara H., Di Mario U. Up-regulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation endproducts (AGEs) via a receptor-mediated mechanism. Diabetes 1997, 46: 1881-1887.
271. Lu M., Kuroki M., Amano S., Tolentino M., Keough K., Kim I., Bucala R., Adamis A.P. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J. Clin. Invest. 1998, 101: 1219-1224.
272. Vlassara H., Brownlee M., Manogue K.R., Dinarello C.A., Pasagian A. Catechin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988, 240: 1546-1548.
273. Kirstein M., Brett J., Radoff S., Ogawa S., Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc. Natl. Acad. Sci. USA 1990, 87: 9010-9014.
274. Kirstein M., Aston C., Hints R., Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J. Clin. Invest. 1992, 90: 439-446.
275. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J. Clin. Invest. 1991, 87: 432-438.
276. Bierhaus A., Chevion S., Chevion M., Hofmann M., Quehenberger P., Illmer T., Luther T., Berentshtein E., Tritschler H., Muller M., Wahl P., Ziegler R., Nawroth P.P. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997, 46: 1481-1490.
277. Schmidt A.M., Hori O., Chan J.X., Li J.F., Crandall J., Zhang J., Cao R., Yan S.D., Brett J., Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J. Clin. Invest. 1995, 96: 1395-1403.
278. Esposito C., Gerlach H., Brett J., Stern D., Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J. Exp. Med. 1989, 170: 1387-1407.
279. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 1997, 272: 17810-17814.
280. Simm A., Munch G., Seif F., Schenk O., Heifland A., Richter H., Vamvakas S., Schinzel R. AGEs stimulated MAPK and its down stream target, the AP-1 complex, in tubulus cell line LLC-PK1. FEBS Lett. 1997, 410: 481-484.
281. Soulis-Liparota T., Cooper M., Papazoglou D., Clarke B., Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 1991, 40: 1328-1334.
282. Edelstein D., Brown lee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992, 41: 26-29.
283. Nakamura S., Makita Z., Ishikawa S., Yasumura K., Fuji W., Yanagisawa K., Kawata T., Koike T. Progression of nephropathy in spontaneous diabetic rats is prevented by OBP-9195, a novel inhibitor of advanced glycation. Diabetes 1997, 46: 895-899.
284. Youssef S., Nguyen D.T., Soulis T., Panagiotopoulos S., Jerums G., Cooper M.E. Effect of aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int. 1999, 55: 907-916.
285. Cohen M.P., Ziyadeh F.N. Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. J. Am. Soc. Nephrol. 1996, 7: 183-190.
286. Ziyadeh F.N., Han D.C., Cohen J.A., Guo J., Cohen M.P. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cell: involvement of the transforming growth factor-beta system. Kidney Int. 1998, 53: 631-638.
287. Cohen M.P., Sharma K., Jin Y., Hud E., Wu V.-Y., Tomaszewski J., Ziyadeh F.N. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy. J. Clin. Invest. 1995, 95: 2338-2345.
288. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 1991, 40: 405-412.
289. Lee A.Y., Chung S.S. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J. 1999, 13: 23-30.
290. Williamson J.R., Chang K., Frangos M., Hasan K.S., Ido Y., Kawamura T., Nyengaard J.R., Van Den Enden M., Kilo C., Tilton R.G. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993, 42: 801-813.
291. Yan S.D., Schmidt A.M., Anderson G.M., Zhang J., Brett J., Zou Y.S., Pinsky D., Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 1994, 269: 9889-9897.
292. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996, 19: 257-267.
293. Kashiwagi A., Asahina T., Nishio Y., Ikebuchi M., Tanaka Y., Kikkawa R., Shigeta Y. Glycation, oxidative stress, and scavenger activity: glucose metabolism and radical scavenger dysfunction in endothelial cells. Diabetes 1996, 45 (Suppl. 3): S84-S86.
294. +. Kidney Int. 1992, 41: 778-788.
295. Ha H., Yoon S.J., Kim K.H. High glucose can induce lipid peroxidation in the isolated rat glomeruli. Kidney Int. 1994, 46: 1620-1626.
296. Reddi A.S., Bollineni J.S. Renal cortical expression of mRNAs for antioxidant enzymes in normal and diabetic rats. Biochem. Biophys. Res. Commun. 1997, 235: 598-601.
297. Bierhaus A., Hofmann M.A., Ziegler R., Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res. 1998, 37: 586-600.
298. Koya D., Haneda M., Kikkawa R., King G.L. D-alpha tocopherol treatment prevents glomerular dysfunctions in diabetic rats through inhibition of protein kinase C-diacylglycerol pathway. Biofactors 1998, 7: 69-76.
299. Tada H., Ishii H., Isogai S. Protective effect of D-alpha tocopherol on the function of human mesangial cells exposed to high glucose concentrations. Metabolism 1997, 46: 779-784.
300. Shan Z., Tan D., Satriano J., Silbiger S., Schlondorff D. Intracellular glutathione influences collagen generation by mesangial cells. Kidney Int. 1994, 46: 388-395.